Fulvestrant Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of fulvestrant during breastfeeding. However, because of its potential toxicity in the breastfed infant and its half-life of 40 days, the manufacturer recommends that breastfeeding be discontinued during fulvestrant therapy and for 1 year after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Fulvestrant
CAS Registry Number
129453-61-8
Drug Class
Breast Feeding
Lactation
Milk, Human
Antineoplastic Agents, Hormonal
Estrogen Receptor Antagonists
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
